Gabapentin
Product Images NDC 70166-751

8 FDA label images from Lohxa · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 70166-751). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lohxa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Principal Display (Gabapentin300 20191219 201208)

Principal Display (Gabapentin300 20191219 201208)
Gabapentin oral solution 300 mg/6 mL label with NDC 70166-751-06. The label indicates it is for oral use only and must be refrigerated. It includes dosing information showing 300 mg per 6 mL and notes 100 units x 6 mL. The product is labeled as repackaged by Lohxa, Worcester, MA, USA, with their website listed.*
FDA Label Image

Equation (Figure 01)

Equation (Figure 01)
An illustration showing the formula to calculate Creatinine Clearance (CLCr), which includes variables for age, weight, serum creatinine, and a factor adjustment for female patients.*
FDA Label Image

Chemical Structure (Figure 02)

Chemical Structure (Figure 02)
Chemical structure diagram of Gabapentin, showing a cyclohexane ring attached to an amino group and a carboxymethyl group, representing its molecular configuration.*
FDA Label Image

Figure 1 (Figure 03)

Figure 1 (Figure 03)
A line graph depicting mean pain scores over an 8-week period during a 4-week dose titration period followed by a 4-week fixed dose period. The graph compares placebo and Gabapentin 3600 mg/day, with pain scores decreasing over time for Gabapentin users while remaining relatively stable for placebo.*
FDA Label Image

Figure 2 (Figure 04)

Figure 2 (Figure 04)
A line graph depicting mean pain score over 7 weeks among three groups: placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The chart includes a 3-week dose titration period and a 4-week fixed dose period, showing pain score trends declining more for Gabapentin groups compared to placebo.*
FDA Label Image

Figure 3 (Figure 05)

Figure 3 (Figure 05)
Bar chart comparing results from two studies labeled Study 1 and Study 2. It shows percentage values on the vertical axis from 0% to 100%, comparing placebo (PBO) with Gabapentin (GBP) doses of 1800, 2400, and 3600. Study 1 compares PBO with GBP 3600; Study 2 compares PBO with GBP 1800 and 2400. Statistical significance markers indicate p-values less than 0.01 and 0.001 for GBP doses versus placebo.*
FDA Label Image

Figure 4 (Figure 06)

Figure 4 (Figure 06)
A scatter plot graph showing the percentage difference on the y-axis versus daily dose in milligrams (mg) on the x-axis, with data points from three studies labeled as Study a, Study b, and Study c. The plot compares differences at doses ranging from 600 mg to 1800 mg daily.*
FDA Label Image

Logo (Figure 07)

Logo (Figure 07)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.